• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, November 12, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

Research: Contact lenses used to slow myopia in youth have lasting benefit

by Staff Writer
January 20, 2025
in Eye disease, International, Myopia, News, Ophthalmic insights, Research
Reading Time: 3 mins read
A A
Research has shown the benefits of sticking with special contact lenses for myopic children. Image: Andrey Sayfutdinov/Shutterstock.com.

Research has shown the benefits of sticking with special contact lenses for myopic children. Image: Andrey Sayfutdinov/Shutterstock.com.

Share on FacebookShare on Twitter

A study funded by America’s National Institutes of Health (NIH) has found that children who wore special contact lenses to slow progression of myopia maintained the treatment benefit after they stopped wearing the contacts as older teens.

A NIH media release said controlling myopia progression in childhood can help to potentially decrease the risks of vision-threatening myopia complications later in life, such as retinal detachment and glaucoma.

“Rates of myopia have been increasing in recent years with some implications that higher use of personal devices plays a role,” the release said.

“There was concern that the eye might grow faster than normal when myopia-control contact lenses were discontinued,” said principal investigator, Dr David A. Berntsen, chair of clinical sciences at the University of Houston College of Optometry.

But the new study showed that axial eye growth returned to age-expected rates. While there was a small increase (0.03 mm/year) in eye growth across all age groups after discontinuing multifocal lenses, the overall rate of eye growth was no different than the age-expected rate.

“Our findings show that when older teenagers stopped wearing these lenses, the eye returned to the age-expected rate of growth,” said Dr Berntsen.

The new study follows an original clinical trial that showed soft contact lenses designed to add high focusing power to one’s peripheral vision, as well as correction for distance vision, were most effective at slowing the rate of eye growth, decreasing how myopic children became.

Participants in the follow-up study wore high-add lenses for two years, followed by single-vision contact lenses for the third year of the study to see if the benefit remained after discontinuing treatment.

Participants who had been in the original study high-add multifocal treatment group continued to have shorter eyes and less myopia at the end of the follow-up study, the release said.

Children who were switched to high-add multifocal contact lenses for the first time during the follow-up study did not catch up to those who had worn high-add lenses since the start of the original clinical trial when they were 7 to 11 years of age.

“Our findings suggest that it’s a reasonable strategy to fit children with multifocal contact lenses for myopia control at a younger age and continue treatment until the late teenage years when myopia progression has slowed,” said follow-up study chair, Dr Jeffrey J. Walline, associate dean for research at the Ohio State University College of Optometry, Columbus.

Single vision prescription glasses and contact lenses can correct myopic vision, but they fail to treat the underlying problem, which is the eye continuing to grow longer than normal. By contrast, soft multifocal contact lenses correct myopic vision in children while simultaneously slowing myopia progression by slowing eye growth.

The study, known as the Bifocal Lenses In Nearsighted Kids (BLINK), and follow-on study, known as BLINK2 published their findings in JAMA Ophthalmology.

More reading

Myopia Navigator tool now available in 126 countries

Combining myopia treatment with UV protection

Glaucoma: Integrating OSD management with peri-operative optometric care

 

Related Posts

Essilor Stellest lens are now approved for the US market. Image: EssilorLuxottica.

Essilor Stellest lens for myopia control gains FDA approval

by Staff Writer
November 12, 2025

EssilorLuxottica has announced the US Food and Drug Administration (FDA) has granted market authorisation for its Essilor Stellest lens using...

The event will bring together leaders to address the escalating burden of childhood myopia worldwide. Image: Serhii/stock.adobe.com

HOYA to host virtual roundtable to tackle childhood myopia crisis

by Staff Writer
November 12, 2025

HOYA Vision Care will host a high-level virtual roundtable this month, spotlighting childhood myopia as a growing global health concern...

Workforce data shows orthoptists independently screen, triage, and monitor eye conditions. Image: Viacheslav Yakobchuk/stock.adobe.com.

Capturing the orthoptic workforce in 2025

by Amanda French
November 11, 2025

Orthoptics Australia’s 2025 Workforce Survey reveals critical insights into a growing, diversifying profession – addressing data gaps vital for future...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited